Trial Profile
Phase II Study of LY353381-HC1 Administered to Women With Refractory Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Arzoxifene (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 17 Sep 2005 New trial record.